342 related articles for article (PubMed ID: 33809587)
1. Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Rinninella E; Strippoli A; Cintoni M; Raoul P; Vivolo R; Di Salvatore M; Genco E; Manfredi R; Bria E; Tortora G; Gasbarrini A; Pozzo C; Mele MC
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33809587
[TBL] [Abstract][Full Text] [Related]
2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
[TBL] [Abstract][Full Text] [Related]
5. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
6. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
7. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
8. Results of the observational prospective RealFLOT study.
Giommoni E; Lavacchi D; Tirino G; Fornaro L; Iachetta F; Pozzo C; Satolli MA; Spallanzani A; Puzzoni M; Stragliotto S; Sisani M; Formica V; Giovanardi F; Strippoli A; Prisciandaro M; Di Donato S; Pompella L; Pecora I; Romagnani A; Fancelli S; Brugia M; Pillozzi S; De Vita F; Antonuzzo L
BMC Cancer; 2021 Oct; 21(1):1086. PubMed ID: 34625033
[TBL] [Abstract][Full Text] [Related]
9. Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.
Huemer F; Hecht S; Scharinger B; Schlintl V; Rinnerthaler G; Schlick K; Heregger R; Melchardt T; Wimmer A; Mühlbacher I; Koch OO; Neureiter D; Klieser E; Seyedinia S; Beheshti M; Greil R; Weiss L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3051-3064. PubMed ID: 35864270
[TBL] [Abstract][Full Text] [Related]
10. Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data.
Egebjerg K; Andersen TS; Bæksgaard L; Garbyal R; Siemsen M; Achiam M; Mau-Sørensen PM
Acta Oncol; 2024 May; 63():322-329. PubMed ID: 38745482
[TBL] [Abstract][Full Text] [Related]
11. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
12. FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
Zhang S; Yan D; Sun Q; Du T; Cao D; Yang Y; Yuan B; Li H; Jiang X; Song C
Can J Gastroenterol Hepatol; 2020; 2020():1702823. PubMed ID: 32566545
[TBL] [Abstract][Full Text] [Related]
13. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
Gürler F; İlhan A; Güven DC; Turhan O; Kurt İnci B; Sütçüoğlu O; Yildiz F; Arik Z; Öksüzoğlu B; Yalçin Ş; Özdemir N; Yazici O; Özet A
Anticancer Drugs; 2022 Jan; 33(1):e477-e485. PubMed ID: 34261917
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
15. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
[TBL] [Abstract][Full Text] [Related]
16. Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Quesada S; Samalin E; Thezenas S; Khellaf L; Mourregot A; Portales F; Mazard T; Ychou M; Adenis A
Anticancer Res; 2022 Jan; 42(1):185-193. PubMed ID: 34969724
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
Lorenzen S; Götze TO; Thuss-Patience P; Biebl M; Homann N; Schenk M; Lindig U; Heuer V; Kretzschmar A; Goekkurt E; Haag GM; Riera-Knorrenschild J; Bolling C; Hofheinz RD; Zhan T; Angermeier S; Ettrich TJ; Siebenhuener AR; Elshafei M; Bechstein WO; Gaiser T; Loose M; Sookthai D; Kopp C; Pauligk C; Al-Batran SE;
J Clin Oncol; 2024 Feb; 42(4):410-420. PubMed ID: 37963317
[TBL] [Abstract][Full Text] [Related]
19. Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
Monti M; Prochowski Iamurri A; Bianchini D; Gallio C; Esposito L; Montanari D; Ruscelli S; Molinari C; Foca F; Passardi A; Vittimberga G; Morgagni P; Frassineti GL
Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630794
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
